KCT0000663已完成未知
An open-label, randomized, single-dose, 2-way crossover trial to compare the pharmacokinetic properties after coadministration of Metformin hydrochloride and Repaglinide, or Administration of combination preparation of Metformin hydrochloride and Repaglinide in healthy male volunteers.
Dalim BioTech0 个研究点目标入组 50 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 20(Year) 至 55(Year)（—）
- 性别
- Male
入选标准
- •(1) Healthy male volunteers ages between 20 and 55 years at screening
- •(2) Subject with Body Mass Index(BMI) with the range of 17.5 to 30.5kg/m2 and body weight over 45kg
- •(3) Signed informed consent with the date of signature
- •(4) With ability to comply with all the scheduled visits, treatment plans; laboratory tests and other processes.
排除标准
- •(1) Positive of blood, kidney, endocrine, lung, gastro-intestinal, cardiovascular, hepatic, psychiatric, nervous, allergy; or with past and present disease history or symptoms that are clinically significant.
- •(2) Any conditions that are likely to affect drug absorption. ex) gastrectomy.
- •(3) Positive on urine drug tests.
- •(4) History of drinking alcohol more than 12 ounces(360mL) of beer, 1.5 ounces(45mL) of liquor; or 21 drinks/week(1drink = 5 ounces(150mL) of wine ) 6months prior to screening.
- •(5) Participation in any other clinical studies within 2months prior to scheduled study drug administration.
- •(6) With Blood pressure of = 160 mmHg(Systolic blood pressure) or = 90 mmHg(Diastolic blood pressure) in sitting position at screening time.
- •(7) History of any serious substance or alcohol abuse within one year prior to screening.
- •(8) Use of any drugs known to significantly induce or inhibit drug metabolizing enzyme within 30days prior to scheduled study drug administration.
- •(9) Cigarette smoking of over 20 sticks per day.
- •(10) Use of any prescription drugs or any over the counter drugs within 10days or quintuple half life(whichever is longer) prior to scheduled study drug administration.
- •(11) Donation of whole blood within 2months or any blood products within 1month, prior to scheduled study drug administration.
- •(12) Disability to comply with the guidelines written on the protocol.
- •(13) Severe acute/chronic medical, physical disorder or laboratory test abnormality that are likely to alter the study result and increase the risk by participating in the study and study drug administration.
- •(14) Hypersensitivity to chief component or excipient of Repaglinide.
- •(15) History of hypersensitivity to Metformin or Biguanide class of drugs.
- •(16) With renal failure or renal inadequacy caused by cardiovascular shock, acute myocardial infarction and sepsis.
- •(17) With Congestive heart failure and undergoing drug treatment.
- •(18) Patients undergoing radioactive iodine uptake tests, such as intravenous urography, intravenous cholangiography, angiography, computed tomography using radioactive iodine.
- •(19) Patients with type 1 diabetes, acute or chronic metabolic acidosis including diabetic ketoacidosis associated with or without coma.
- •(20) With serious infection or trauma.
- •(21) Malnutrition, starvation; weakness; pituitary insufficiency or adrenal insufficiency.
- •(22) Patients with hepatic failure, pulmonary infarction, serious pulmonary dysfunction, or other conditions associated with hypoxemia, alcohol abuser, or dehydration, diarrhea; vomiting and gastro-intestinal disease.
- •(23) Proven to be unsuitable to participate in this clinical study by an investigator.
研究者
相似试验
已完成
不适用
A randomized, open-label, single dose two-way cross-over pharmacokinetic study of 3D-printed sildenafil tablets compared to the originator sildenafil tablets in healthy adultsNL-OMON49936eids Universitair Medisch Centrum12
招募中
不适用
An open-label, randomized, single-dose, 2way crossover study to compare the pharmacokinetics of Traclear 62.5 mg 2 tablets and HGP1206 125 mg 1 tablet in healthy male volunteersKCT0000802Hanmi Pharm28
已完成
不适用
A Phase 1 Clinical Trial to Investigate Pharmacokinetics and Bioequivalence of the co-administration of telmisartan and rosuvastatin and YH16410KCT0001231Yuhan180
进行中（未招募）
不适用
A randomized, open-label, single-dose, 2-way cross-over study to compare the safety and the pharmacokinetic characteristics of CPBI402 in healthy male volunteersDiseases of The genitoruinary systemKCT0001767Corepharmbio34
进行中（未招募）
不适用
A single-dose, open-label, randomized, 2-way crossover, clinical pharmacology study of four inhalations of CHF 1535 100/6 NEXT DPI® (fixed combination of beclomethasone dipropionate 100µg plus formoterol fumarate 6 µg) versus the same dose of CHF 1535 100/6 pMDI both administered with charcoal block. - (duplicate) Clinical pharmacology study of CHF1535 NEXT DPI versus CHF1535 pMDIMedDRA version: 13.1Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersAsthmaEUCTR2010-024384-40-GBChiesi Farmaceutici S.p.A.24